Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Toplak, H; Bilitou, A; Alber, H; Auer, J; Clodi, M; Ebenbichler, C; Fließer-Görzer, E; Gelsinger, C; Hanusch, U; Ludvik, B; Maca, T; Schober, A; Sock, R; Speidl, WS; Stulnig, TM; Weitgasser, R; Zirlik, A; Koch, M; Wienerroither, S; Wolowacz, SE; Diamand, F; Catapano, AL.
Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients.
Wien Klin Wochenschr. 2023; 135(13-14): 364-374.
Doi: 10.1007/s00508-023-02221-4
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Toplak Hermann
- Co-authors Med Uni Graz
- Zirlik Andreas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- OBJECTIVE: The low-density lipoprotein cholesterol goals in the 2019 European Society of Cardiology/European Atherosclerosis Society dyslipidaemia guidelines necessitate greater use of combination therapies. We describe a real-world cohort of patients in Austria and simulate the addition of oral bempedoic acid and ezetimibe to estimate the proportion of patients reaching goals. METHODS: Patients at high or very high cardiovascular risk on lipid-lowering treatments (excluding proprotein convertase subtilisin/kexin type 9 inhibitors) from the Austrian cohort of the observational SANTORINI study were included using specific criteria. For patients not at their risk-based goals at baseline, addition of ezetimibe (if not already received) and subsequently bempedoic acid was simulated using a Monte Carlo simulation. RESULTS: A cohort of patients (N = 144) with a mean low-density lipoprotein cholesterol of 76.4 mg/dL, with 94% (n = 135) on statins and 24% (n = 35) on ezetimibe monotherapy or in combination, were used in the simulation. Only 36% of patients were at goal (n = 52). Sequential simulation of ezetimibe (where applicable) and bempedoic acid increased the proportion of patients at goal to 69% (n = 100), with a decrease in the mean low-density lipoprotein cholesterol from 76.4 mg/dL at baseline to 57.7 mg/dL overall. CONCLUSIONS: The SANTORINI real-world data in Austria suggest that a proportion of high and very high-risk patients remain below the guideline-recommended low-density lipoprotein cholesterol goals. Optimising use of oral ezetimibe and bempedoic acid after statins in the lipid-lowering pathway could result in substantially more patients attaining low-density lipoprotein cholesterol goals, likely with additional health benefits.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Ezetimibe - therapeutic use
- Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
- Anticholesteremic Agents - therapeutic use
- Austria - administration & dosage
- Fatty Acids - adverse effects
- Cholesterol, LDL - administration & dosage
- Find related publications in this database (Keywords)
- Lipid lowering therapy
- ComBination therapy
- Ezetimibe
- Bempedoic acid
- Cardiovascular
- Atherosclerosis